Key result
Vitamin E may reduce cardiovascular events specifically in diabetic patients with the haptoglobin 2-2 genotype.
Answers are grounded in this paper and cite their sources.
Vitamin E is a naturally occurring fat-soluble antioxidant which has been proposed as a treatment for both primary and secondary protection against cardiovascular (CV) events. Promising data from observational epidemiological studies associating higher vitamin E dietary intake with lower risk of CV events have not been validated in randomized controlled clinical trials assessing the effect of vitamin E on CV outcomes. While the pendulum of medical opinion has swung to suggest that high dose vitamin E supplements have no place in the treatment and prevention of CV disease, new data is emerging that allows identification of a specific target population for this treatment, namely patients with diabetes mellitus and the haptoglobin genotype 2-2. This review details the scientific basis and clinical evidence related to the effect of vitamin E on CV outcomes, and the importance of proper patient selection in gaining therapeutic benefit from this intervention.
No takes yet. Share an insight, caveat, or question.
Vardi et al. (2013) conducted a review in Cardiovascular disease prevention in diabetes mellitus with haptoglobin genotype 2-2. Vitamin E supplementation was evaluated on Cardiovascular events. Vitamin E supplementation may provide cardiovascular benefit specifically in patients with diabetes mellitus and the haptoglobin 2-2 genotype, despite null findings in broader randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: